Flavoxate HCl(Rec-7-0040 DW61)

Molecular Weight (MW)	427.92
Formula	C24H25NO4.HCl
CAS No.	3717-88-2
Storage	-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 3 mg/mL (7.0 mM)
Water: 10 mg/mL (23.4 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)	30% Propylene glycol, 5% Tween 80, 65% D5W: 30 mg/mL
Synonyms	Rec-7-0040; DW-61; NSC-114649; Rec 7-0040; DW 61; NSC 114649; Rec7-0040; DW61; NSC114649

Molecular Weight (MW)

427.92

Formula

C24H25NO4.HCl

CAS No.

3717-88-2

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: 3 mg/mL (7.0 mM)

Water: 10 mg/mL (23.4 mM)

Ethanol: <1 mg/mL

Solubility (In vivo)

30% Propylene glycol, 5% Tween 80, 65% D5W: 30 mg/mL

Synonyms

Rec-7-0040; DW-61; NSC-114649; Rec 7-0040; DW 61; NSC 114649; Rec7-0040; DW61; NSC114649

In Vitro	In vitro activity: Flavoxate displaces [3H]nitrendipine on the Ca2+ channels binding sites with IC50 of 254 μM. Flavoxate (>10 μM) suppresses carbachol-induced contractions in isolated rat detrusor strips with pD value of 4.55. Flavoxate (>10 μM) suppresses Ca2+-induced contractions in isolated rat detrusor strips with pIC50 value of 4.92. Flavoxate (0.01 μM –10 μM) inhibits CAMP formation in a concentration-dependent manner in membranes from the rat striatum and cerebral cortex, an action which is completely abolished by pretreating the membranes with pertussis toxin (PTX). Flavoxate causes a concentration-dependent reduction of the K+-induced contraction of human urinary bladder. Flavoxate inhibits the peak amplitude of voltage-dependent nifedipine-sensitive inward Ba2+ currents in a voltage- and concentration-dependent manner with Ki value of 10 μM in human detrusor myocytes.
In Vivo	Flavoxate (10mg/kg) suppresses both the an initial, rapidly rising phasic contraction (phase 1) and the tonic contraction (phase 2) contractions to the same extent in rats. Flavoxate (10mg/kg) abolishes the bladder contractions without causing any change in the amplitude of the contractions in rats. Flavoxate (3 mg/kg) abolishes the efferent neural activity and the associated bladder contractions for about 10 minutes without changing the baseline vesical pressure in rats. ICV-injected (50 to 200 μg/rat) or IT-injected (100 to 200 μg/rat) Flavoxate abolishes rhythmic bladder contractions during and after injection for five to 15 minutes in a dose-dependent manner in rats. Flavoxate (3 mg/kg, i.v.) abolishes rhythmic bladder contractions and the maximal intervals of voiding contractions is 7.20 min.
Animal model	Sprague-Dawley rats
Formulation & Dosage	Dissolved in saline; 10 mg/kg; i.v. injection
References	Int J Urol. 1996 May;3(3):218-27; Brain Res. 1996 Jul 15;727(1-2):91-8.

In Vitro

In vitro activity: Flavoxate displaces [3H]nitrendipine on the Ca2+ channels binding sites with IC50 of 254 μM. Flavoxate (>10 μM) suppresses carbachol-induced contractions in isolated rat detrusor strips with pD value of 4.55. Flavoxate (>10 μM) suppresses Ca2+-induced contractions in isolated rat detrusor strips with pIC50 value of 4.92. Flavoxate (0.01 μM –10 μM) inhibits CAMP formation in a concentration-dependent manner in membranes from the rat striatum and cerebral cortex, an action which is completely abolished by pretreating the membranes with pertussis toxin (PTX). Flavoxate causes a concentration-dependent reduction of the K+-induced contraction of human urinary bladder. Flavoxate inhibits the peak amplitude of voltage-dependent nifedipine-sensitive inward Ba2+ currents in a voltage- and concentration-dependent manner with Ki value of 10 μM in human detrusor myocytes.

In Vivo

Flavoxate (10mg/kg) suppresses both the an initial, rapidly rising phasic contraction (phase 1) and the tonic contraction (phase 2) contractions to the same extent in rats. Flavoxate (10mg/kg) abolishes the bladder contractions without causing any change in the amplitude of the contractions in rats. Flavoxate (3 mg/kg) abolishes the efferent neural activity and the associated bladder contractions for about 10 minutes without changing the baseline vesical pressure in rats. ICV-injected (50 to 200 μg/rat) or IT-injected (100 to 200 μg/rat) Flavoxate abolishes rhythmic bladder contractions during and after injection for five to 15 minutes in a dose-dependent manner in rats. Flavoxate (3 mg/kg, i.v.) abolishes rhythmic bladder contractions and the maximal intervals of voiding contractions is 7.20 min.

Animal model

Sprague-Dawley rats

Formulation & Dosage

Dissolved in saline; 10 mg/kg; i.v. injection

References

Int J Urol. 1996 May;3(3):218-27; Brain Res. 1996 Jul 15;727(1-2):91-8.

CAS NO:	3717-88-2
规格:	≥98%

包装	价格(元)
250mg	电议
500mg	电议
1g	电议
2g	电议
5g	电议
10g	电议
25g	电议